Keep On Keep Up Bladder Health: Co-creating and Testing a Self-management Technological Solution for Ageing Well
NCT ID: NCT06583733
Last Updated: 2025-03-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
120 participants
INTERVENTIONAL
2025-03-24
2028-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Urinary Incontinence Self-Screen for Healthy Aging
NCT03485872
Outcomes of Urinary Incontinence Treatment in Primary Care: APP Co-Management and Electronic Consult
NCT06040645
Think Dry: Optimalisation of Diagnostic Process of Urinary Incontinence in Older People
NCT04094753
Treatment of Overactive Bladder With a Digital Conversational Agent: the MOTIVATION Study
NCT04853849
Improving Overactive Bladder Treatment Access and Adherence
NCT06094543
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Phase II (M2-5): Consultation with 4-6 experts on Badder Health (BH) and/or behavioral interventions. Develop a first iteration of the eHealth method and module.
Conduct an initial online focus group with 10-12 co-creators of UK to explore their perceived acceptability and feasibility and preferences for the eHealth program (concept development through co-creation).
Develop a first iteration of the eHealth method and module (concept development) - by Reason Digital (tech company in Manchester)
Phase III (M6-14): Organize, conduct and analyze 5 more focus group (2 in Lithuania, 1 UK and 2 Spain) with 10-12 co-creators each (community-dwelling people aged 50+ of both genders with different physical conditions and UI, health professionals and stakeholders with different backgrounds) to explore their perceived acceptability and feasibility and preferences for the eHealth program (concept development through co-creation). Secondment in University of Manchester.
Phase IV (M14-M20): Further develop the eHealth module (concept development) - by Reason Digital (tech company in Manchester)
Phase V (M21-36): Multicenter two-armed feasibility RCT study with at least 120 participants (WP3). Participants will be randomized to a control (recommendations for self- managing urinary symptoms) or intervention (KOKU Bladder) group.
Phase VI: Early and open communication and dissemination (WP4). Analysis of results.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
control group
The control group which will receive recommendations for self- managing urinary symptoms.
There will be at least 60 participants (men and women mixed) distributed in 3 countries. It is anticipated that the multicomponent intervention will last 12 weeks.
After the intervention we will collect the results with a mixed (qualitative and quantitative) approach.
recommendations
In this intervention the participants will receive recommendations for self- managing urinary symptoms, which they must follow for 12 weeks.
After the intervention we will collect the results with a mixed (qualitative and quantitative) approach. Qualitative information will be recorded and analysed through thematic analysis, and quantitative data will be collected with tests and questionnaires.
intervention group
The intervention group, which will receive the treatment with KOKU Bladder. There will be at least 60 participants (men and women mixed) distributed in 3 countries. It is anticipated that the multicomponent intervention will last 12 weeks.
After the intervention we will collect the results with a mixed (qualitative and quantitative) approach.
KOKU Bladder
In this intervention the participants will receive treatment with the KOKU app ( based digital health program with behavior change techniques to improve bladder health ) for 12 weeks.
After the intervention we will collect the results with a mixed (qualitative and quantitative) approach. Qualitative information will be recorded and analysed through thematic analysis, and quantitative data will be collected with tests and questionnaires.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
KOKU Bladder
In this intervention the participants will receive treatment with the KOKU app ( based digital health program with behavior change techniques to improve bladder health ) for 12 weeks.
After the intervention we will collect the results with a mixed (qualitative and quantitative) approach. Qualitative information will be recorded and analysed through thematic analysis, and quantitative data will be collected with tests and questionnaires.
recommendations
In this intervention the participants will receive recommendations for self- managing urinary symptoms, which they must follow for 12 weeks.
After the intervention we will collect the results with a mixed (qualitative and quantitative) approach. Qualitative information will be recorded and analysed through thematic analysis, and quantitative data will be collected with tests and questionnaires.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Self-reported UI (at least 1 leakage/month)
* Ability to read and understand the national languages
* Have a mobile phone/tablet
* Sign informed consent.
Exclusion Criteria
* Unstable health conditions.
50 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Universitari Santa Maria de Lleida (GSS)
UNKNOWN
Institut de Recerca i Innovació en Ciències de la Vida i de la Salut a la Catalunya Central (IRIS)
UNKNOWN
University of Manchester
OTHER
Research Council of Lithuania
OTHER
Lithuanian Sports University
OTHER
Agencia Gestió Ajuts Universitaris i Recerca
UNKNOWN
Consorci Hospitalari de Vic (CHV)
UNKNOWN
University of Vic - Central University of Catalonia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Javier Jerez Roig
Professor, Head of research group on Methodology, Methods, Models and Outcomes of Health and Social Science (M3O)
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jerez-Roig, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Vic-Central University of Catalonia; Lithuanian Sports University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lithuanian Sports University
Kaunas, , Lithuania
Hospital Santa Maria
Lleida, , Spain
Hospital Consortium of Vic
Vic, , Spain
University of Manchester
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Eva Borralleras-Fumaña
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Jerez-Roig J, Aguila-Gimeno O, Brazaitis M, Solianik R, Karkauskiene E, Jarutiene L, Fuente-Vidal A, Borralleras-Fumana E, Gasteiger N, Stanmore E. Co-creating and testing a self-management digital solution for bladder health and urinary continence among people aged 50 and over: protocol for the international KOKU Bladder project. BMJ Open. 2025 Sep 11;15(9):e100487. doi: 10.1136/bmjopen-2025-100487.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KOKU Bladder
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.